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Abstract
Inflammation is postulated to play an important role in ovarian carcinogenesis. Prostaglandin
endoperoxide synthase 2 (PTGS2) is responsible for the conversion of arachidonic acid to
prostaglandins in response to inflammation. We examined the association of the PTGS2 rs5275
polymorphism with the risk of invasive ovarian carcinoma and the joint effect of rs5275 and use
of nonsteroidal antiinflammatory drugs (NSAIDs) on risk in a pooled analysis of two population-
based studies, the Hawaii Ovarian Cancer Case-Control Study and the New England Case-Control
Study, including 1025 women with invasive ovarian carcinoma and 1687 cancer-free controls.
Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic
regression. In the pooled analysis, the CC genotype was associated with a reduced risk of
nonserous ovarian carcinoma (OR=0.66; CI: 0.44-0.98). In addition, the lowest risk was observed
among carriers of the CC genotype who were users of nonaspirin NSAIDs (OR=0.43; CI:
0.20-0.93) in all women combined. The association of PTGS2 rs5275 with nonserous ovarian
carcinoma and possible effect modification by NSAID use needs further validation, preferably in
the prospective studies.
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The ovarian surface epithelium contributes to ovulation by lysis and reconstruction of the
ovarian cortex, and is thought to be the source of 90% of ovarian neoplasms (1). Repeated
episodes of ovulation-associated injury may contribute to ovarian carcinoma pathogenesis
(2). Ovulation is associated with an inflammatory response in mature follicles (3,4) that
leads to the release of reactive nitrogen and oxygen species directly damaging DNA,
dysregulation of cytokines associated with neoplastic progression, and overexpression of
prostaglandins increasing tumor invasiveness (5,6). Hence, postovulatory tissue repair
occurs in an environment that potentiates and promotes neoplastic risk. Both animal models
and observational studies in humans demonstrate that some potent nonsteroidal
antiinflammatory drugs (NSAIDs) can inhibit the ovulatory process (3). An inverse relation
between the use of NSAIDs and the risk of ovarian cancer has been suggested (7); however,
no compelling evidence was provided in further investigations (8,9).
NSAIDs interfere with prostaglandin biosynthesis by inhibiting cyclooxygenases-1 and -2
(COX1 and COX2), also known as prostaglandin endoperoxide synthases (PTGSs). Both
enzymes catalyze the rate-limiting step in prostaglandin synthesis from arachidonic acid
(10). PTGS1 is constitutively expressed in most tissues; in contrast, PTGS2 is induced by
various stimuli including several mitogens, cytokines, growth factors, and tumor promoters
(11). Increased expression of PTGS2 has been linked to inflammatory processes and ovarian
cancer (12,13,14,15).
PTGS2 expression varies among individuals, and this variability may be influenced by
common polymorphisms in the functional regions of the gene (16). Recent investigations
suggest that PTGS2 expression is regulated via the 3′untranslated region (UTR) of the gene.
This evidence was further substantiated by experiments directly showing that the PTGS2
3′UTR confers posttranscriptional regulation through rapid mRNA turnover and
translational inhibition (17). The rs5275 SNP is located in the 3′UTR of the PTGS2 gene,
and the C allele has been associated with lower steady-state PTGS2 mRNA levels (18).
PTGS2 is a small gene with only five common SNPs that are in strong linkage
disequilibrium. All five common SNPs in the PTGS2 gene described to date have been
genotyped in two Nurses’ Health Studies and the Harvard Women’s Health Study. The
rs5275 SNP was the only SNP associated with breast cancer risk in all three studies (19). In
a pooled analysis (1270 cases and 1762 controls), women homozygous for the rs5275 C
allele had a 20% lower risk of breast cancer than common allele homozygotes (19).
In this analysis, data from the Hawaii Ovarian Cancer Case-Control and the New England
Case-Control Study of Ovarian Cancer (NECC) were pooled to test the hypothesis that the
PTGS2 rs5275 C allele is associated with decreased ovarian cancer risk, and that this
association is modified by NSAID use. Both studies are part of the Ovarian Cancer
Association Consortium, a forum for researchers to evaluate genetic associations with
ovarian cancer with increased power (20).
Materials and methods
The Hawaii Ovarian Cancer Case-Control Study (HAW) is a population-based study that
includes women 18 years of age or older who were diagnosed with primary histologically-
confirmed epithelial ovarian cancer between 1993 and 2008. Incident cases were identified
through the rapid-reporting system of the Hawaii Tumor Registry, which is part of the
Surveillance, Epidemiology, and End-Results Program of the National Cancer Institute.
Control subjects were randomly selected from participants in an annual survey of
representative households, conducted by the Hawaii Department of Health under statutory
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provision resulting in almost 100% participation rates. Only invasive ovarian carcinoma
cases (n=302) were included in this analysis. Controls (n=592) were frequency-matched to
cases based on ethnicity and 5-year age groups in an approximate 1:2 ratio. Eligibility
criteria for controls included age 18 years or older, residency in Hawaii for a minimum of
one year, no prior history of ovarian cancer, and having at least one intact ovary. The
response rate was 65% for cases and 68% for controls. Socio-demographic, life style, and
health-related information was collected during a ~2.5-hour interview, using a structured
pre-tested questionnaire (21). Detailed history of NSAID use was available for 217 cases
and 419 controls who completed a questionnaire revised in 2001 that included NSAID use.
To distinguish occasional versus long-term users of NSAIDs, participants were asked
whether they ever used NSAIDs 12 or more times during a single year. Those who answered
‘yes’ were asked to provide detailed information on frequency of specific medications used,
numbers of episodes of use, and duration of each episode. Women who used NSAIDs
continuously for 6 months or longer were classified as long-term NSAID users. Interviewers
were uniformly trained and supervised to standardize interviewing and coding techniques.
The New-England Case-Control Study of Ovarian Cancer (NECC) is a population-based
study in New Hampshire and eastern Massachusetts that began in 1998 (22). Histologically-
confirmed incident ovarian cancer cases are identified through hospital tumor boards and
statewide cancer registries. Controls were selected through a combination of random digit
dialing, town books, and drivers’ license lists, and were matched to the distribution of cases
by age and study center. Epidemiological data was collected by in-person administered
questionnaires that included information about demographics, menstrual and reproductive
history, medical and family history, and personal habits. Women were asked whether they
had continuously (at least once a week) used NSAIDs for at least 6 months. Detailed history
on the specific NSAID medication, frequency, and length of use was collected (23). The
NECC study contributed information from 723 women with invasive ovarian carcinoma and
1095 controls for the replication analysis of the PTGS2 rs5275 association with ovarian
cancer risk.
Clinical and questionnaire data from both studies were merged into a common data set at the
Ovarian Cancer Association Consortium (OCAC) coordinating center at Duke University.
The combined data set used in the pooled analysis included 1025 cases and 1687 controls.
The following characteristics were available for all participants: case-control status, age at
diagnosis/interview, race/ethnicity, education, tumor behavior and histologic subtype, family
history of breast and/or ovarian cancer among first-degree female relatives (mothers and
sisters) menopausal status, use of contraceptive steroids and menopausal hormones (estrogen
alone or in combination with progestin), history of tubal ligation, and hysterectomy.
Information on NSAID use was available for 940 cases and 1514 controls that included all
women interviewed after 2001 (217 cases and 419 controls) from the Hawaii study and all
NECC study participants.
The Hawaii study protocol was approved by the Institutional Review Board of the
University of Hawaii. The NECC study protocol was approved by the Human Subjects
Review Committees at both Brigham and Women’s Hospital and Dartmouth Medical
School, and each participant provided signed informed consent. In addition, Duke
University has Institutional Review Board approval as a data coordinating center.
Genotyping
DNA was purified from whole blood using Qiagen Midi Kits (Qiagen, Valencia, CA). At
each site, genotyping was performed using 5′ nuclease TaqMan allelic discrimination assay
(TaqMan, Applied Biosystems, Foster City, CA, USA). Samples from cases and controls
were intermixed on each plate, and laboratory personnel were blinded to the case-control
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status of the study participants. We used the following criteria to measure the acceptability
of the genotyping results: (1) >3% sample duplicates included, (2) concordance rate for
duplicate samples ≥ 98%, (3) overall call rate (by study) >95% and (4) call rate >90% for
each 384-well plate and (5) cases and controls intermixed on each plate. Both studies met
each of the criteria. Gene and allele nomenclature was according to the National Center of
Biotechnology Information (http://www.ncbi.nlm.nih.gov/).
Statistical Analysis
Statistical analysis was performed using SAS version 9.2 (SAS Institute, Cary, NC). A
goodness of fit chi-square test was used to assess whether allele frequency distributions
among controls overall and in each ethnic group were consistent with Hardy-Weinberg
equilibrium. Unconditional multiple logistic regression models were used to calculate odds
ratios (ORs) and 95% confidence intervals (CIs) for the association of the PTGS2 rs5275
genotype with ovarian carcinoma risk. ORs and CIs were estimated separately for
heterozygous and homozygous variant C allele carriers, using women with the TT genotype
as the reference group. We also performed genetic analyses testing a log-additive model in
which genotype was categorized by three levels (0, 1 and 2) representing combinations of
alleles. In addition, we compared risk among heterozygotes and homozygote C allele
carriers combined (testing a dominant genetic model) (data not shown) and among women
with the CC genotype compared to the TT and TC genotypes combined (testing a recessive
genetic model). Based on the Akaike Information Criterion (AIC), the recessive model
provided better fit for the data.
Using data available for the duration of NSAID use, we categorized women who never used
NSAID for 6 months or longer as ‘nonusers’ and women who reported long-term use of
NSAIDs were classified as ‘users’. Among NSAID users, separate analyses were performed
for women who used 1/only acetylsalicylic acid or other salicylates (further referred as
‘aspirin’); 2/ other NSAIDs; 3/ used both; 4/ used any NSAID.
To evaluate potential confounders, the distributions of genotype and NSAID use were
examined by factors associated with ovarian cancer risk in a multiple logistic regression
model. The following covariates were included into all models: age, ethnicity, education,
family history of breast and/or ovarian cancer, menopausal status, use of contraceptive and
menopausal hormones (estrogen alone and in combination with progestin), and, in combined
analyses, study. Heterogeneity of effects by study, NSAID use and other covariates was
examined using a Wald test of the genotype-covariate interaction term. Heterogeneity of
associations of the rs5275 genenotype with risk by histological type (serous, mucinous,
endometrioid, clear cell, and other), was evaluated using Wald tests comparing ORs across
strata by tumor behavior and histology in polytomous logistic regression models. Analyses
were conducted for each study separately and for both studies combined. All p-values were
based on two-tailed tests. Statistical significance was considered at a p value less than 0.05.
Results
Participant characteristics are presented in Table 1. Cases (age: 54.6; SD, 12.0) were slightly
(nonsignificantly) older than controls (age: 52.2; SD, 13.4).The distribution of PTGS2
rs5275 genotypes among control subjects was consistent with Hardy-Weinberg equilibrium
in each stratum by ethnicity and by study and in all strata combined. The rare (C) allele
frequency was higher among white non-Hispanic women (0.34) than among Asian women
(0.22) and among women of mixed/other ethnicity (0.25) (p=0.06), but was similar among
white non-Hispanic women in Hawaii and NECC studies (p for heterogeneity among
genotypes=0.62).
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No significant associations of rs5275 genotype with age, ethnicity, parity, menopausal
status, tubal ligation, hysterectomy, use of contraceptive or menopausal hormones, or
NSAID use were observed (p > 0.05). Use of any NSAIDs was significantly positively
associated with education (p=0.001), and use of contraceptive (p=0.0001) and menopausal
hormones (p <0.0001). Postmenopausal women were significantly more likely to use aspirin
and other salicylates (p<0.0001), and less likely to use nonaspirin NSAIDs (p<0.0001) than
premenopausal women. Among Hawaii participants, women with family history of breast
and/or ovarian cancer were more likely to use both aspirin and nonaspirin NSAIDs than
women who did not report ovarian cancer among first-degree relatives. NSAID use was
significantly associated with decreased ovarian cancer risk (OR=0.79; CI:0.67-0.95).
Significant inverse associations with risk were observed among women who used both
aspirin and nonaspirin NSAIDs, but not among women who used one of these types
exclusively (Table 1).
We did not observe significant associations of PTGS2 genotype with ovarian cancer risk
among all women combined (OR=0.86; CI:0.66-1.12; p for heterogeneity between
studies=0.10) or in the analyses restricted to white women only (Table 2). In sub-group
analyses by study site, we found that homozygous rs5275 C allele carriers had significantly
reduced ovarian cancer risk when compared to carriers of any T allele (recessive genetic
model) (OR=0.51; CI: 0.26-0.98; p=0.04) in the Hawaii study, but not in the NECC study.
No heterogeneity in the association of rs5275 with risk was observed by ethnicity (p for
trend in all models tested ranged from 0.60-0.99; data not shown).
The data were further examined by histological subtype of ovarian cancer (Table 3). Women
with the CC genotype were at significantly reduced risk of nonserous tumors compared to
women with the TT genotype or any T allele carriers (OR=0.66; CI:0.44-0.98; p=0.04)
(recessive genetic model). No association of the PTGS2 rs5275 genotype with risk of serous
cancer was observed.
The joint association of the PTGS2 rs5275 genotype and NSAID use on ovarian carcinoma
risk was examined (Table 4). Women who were CC allele carriers and who were users of
nonaspirin NSAIDs had the lowest risk of ovarian carcinoma compared to women who were
TT genotype carriers and who did not use NSAIDs (OR=0.43; CI:0.20-0.93; p=0.03).
Discussion
In this large pooled analysis of two population-based studies, we explored the association of
the PTGS2 rs5275 polymorphism with invasive ovarian carcinoma risk and the possible
effect modification of the genetic association by NSAID use. We observed a significant 36%
reduction in the risk of nonserous carcinoma among women with the rs5275 CC genotype
compared to women homozygous for the common allele. Interestingly, the most pronounced
decrease in ovarian cancer risk was observed among women who were NSAID users and
homozygous for the rs5275 C allele, although the interaction term for this association was
not statistically significant.
Given its location in the 3′UTR, the rs5275 SNP is a likely candidate to influence
PTGS2RNA half-life, which is controlled by sequence-specific elements in the region of the
mRNA (17). Previous studies have reported that in the proximal upstream region of this
SNP there is a conserved AU-rich sequence element which mediates posttranscriptional
degradation of PTGS2 mRNA (17). A functional analysis measuring PTGS2 mRNA
suggests that the decreased ovarian carcinoma risk associated with the rs5275 C allele may
be attributed to lower PTGS2 expression (18).
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It is biologically plausible that genetic variation in PTGS2 that alters expression levels or the
biochemical function of prostaglandin endoperoxide synthase 2 may influence a woman’s
risk of ovarian carcinoma. PTGS2 converts arachidonic acid to prostaglandin H2, which is a
precursor to all other prostaglandins. Prostaglandins are integral components in the cellular
response to inflammation, promoting cellular proliferation and angiogenesis (24).
NSAID use and PTGS2 genotype may be more strongly associated with endometrioid and
clear cell histologic types of ovarian cancer that are more likely to arise from endometriotic
foci (25). Endometriosis, the presence of endometrial tissue outside the endometrium, causes
a marked local inflammatory reaction (26). In this study, nonserous histological types were
more strongly associated with NSAID use and PTGS2.
Strengths of this study include the population-based nature of both Hawaii and NECC
studies, histologic confirmation of all case diagnoses, stringent genotyping quality control
procedures, and the completeness of epidemiological data related to ovarian cancer risk.
Although the pooled analysis included a relatively large number of cases and controls, the
statistical power was adequate (>90%) to detect ORs of 0.69 and lower at a critical level of
5% (two-sided), using a recessive genetic model. This low risk was present among
nonserous carcinoma cases. Due to the retrospective manner of collecting data on NSAID
use in case-control studies, there is the possibility of recall bias, although participants were
likely unaware of the potential association of NSAID use with ovarian cancer risk.
In summary, we observed an inverse association between a potentially functional SNP in the
3′UTR of the PTGS2 gene and nonserous ovarian carcinoma risk. The potential for a
reduced risk of ovarian cancer among women with the CC genotype who use NSAIDs needs
to be examined further in larger studies, preferably with prospective collection of risk factor
information.
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